



Retina International World Congress 2022

Session labelling: K= Keynote – L= Lay - P = Professional.

Thursday 9th June

17:00 – 19:00 Welcoming ceremony

17:30 - 18:30 **K.1.1 Keynote: Phenotyping and Genotyping in inherited retinal diseases.**

Speaker: Prof. Bart Leroy, University of Ghent, Gent, Belgium.

Friday 10th June

08:30 – 10:00 P.2.1 Age related macular Degeneration.

Moderator: Jóhann Ragnar Guðmundsson

08:30 - 08:50

The MacuStar project

Robert Finger, Department of Ophthalmology, University of Bonn, Bonn, Germany

08:50 - 09:05 AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy and beyond.

Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway. -

09:05 - 09:15 Off-label use of Avastin: Scandinavian disparities.

Speaker: Tomas Bro, MD, PhD, Högländssjukhuset, Eksjö, Sweden

09:15 - 09:25 The risk of extending AMD treatment.

Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden.

09:25 - 09:35 The Swedish Macula Register.

Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden.

09:35 - 09:50 AMD Epidemiology and Genetics. What is important!

Speaker: Prof. emeritus Friðbert Jónasson, University of Iceland, Iceland.

09:50 - 10:00 QnA.

08:30 – 10:00 L.2.1 Retinal degenerations. Clinical aspects.

Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada.



08:30 – 08:50 Clinical aspects of IRD.

Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada.

08:50 - 09:10 Clinical aspects of inherited macular degenerations.

Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.

09:10 – 09:30 Syndromic forms of IRD.

Speaker: prof. Dr. H el ene Dollfus, CARGO, H opitaux Universitaires de Strasbourg, France.

09:30 - 09:50 The genetic testing landscape

Speaker: Avril Daly, Retina International, Dublin, Ireland

09:50 – 10:00 QnA.

10:00 – 10:30 Coffee break.

10:30 – 11:30 P.2.2 Assessment of Endpoints in clinical studies.

Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellstr om, Lund, Sweden.

10:30 – 10:50 How to measure the effects of gene therapy on meaningful vision for patients.

Speaker: Prof. Michael Larsen Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.

10:50 – 11:10 Paediatric specificities in trials.

Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada.

11:10 – 11:30 Gene agnostic approaches

Speaker: Dr. Daniel Chung, DO, MA, Philadelphia, USA

10:30 – 11:30 L.2.2 Retinal degenerations - the genetics.

Moderator: Prof. J on J ohannes J onsson, national University Hospital, Reykjav ik, Iceland.

10:30 – 10:50 Pattern of inheritance - easy to understand.

Speaker: Dr. Eirn y P or lfsd ttir National University Hospital, Reykjav ik, Iceland.



10:50 – 11:10 Understanding the results - a difficult task.

Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland.

11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes.

Speaker: Daníel Þorsteinsson.

11:20 – 11:30 ABCA4 related IRDs

Speaker: Frans Cremers, Radboud University, Nijmegen, Netherlands

11:30 – 12:00 K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception.

Speaker: Christina Fasser, former president of the Retina International, Zurich, Switzerland.

12:00 – 13:30 Lunch

13:30 – 14:00 K.2.2

Keynote: Innovations in Ophthalmology.

Dr. Sabri Markabi

14:00 – 15:00 P.2.3 Phenotype-Genotype Correlations in IRD

Moderators: Josephine Prener Holtan MD, Oslo University Hospital, Oslo, Norway, and Prof. Bart Leroy, Ghent, Belgium.

14.00 - 14.10 Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene.

Speaker: Kristian Lisbjerg, MD, Department of Ophthalmology, Copenhagen University Hospital, Denmark.

14.10 - 14.20 Genetic basis and phenotypic characterization of Danish patients with Achromatopsia.

Speaker: Mette K.G. Andersen, MD, Ophthalmologist at Department of Ophthalmology, Copenhagen University hospital, Rigshospitalet-Glostrup, Denmark.

14.20 - 14.35 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective.

Speaker: Ragnhild Jansson Wivestad, MD, Department of Ophthalmology, Haukeland University Hospital, Norway.



14.35 - 15.00 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe.

Speaker: Professor Helene Dollfuss, MD, PhD, Service de Génétique Médicale, Hôpital de Hautepierre, Strasbourg, France.

14:00 – 15:00 L.2.3 Basics of stem cell and gene-based therapies.

Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA

14:00 - 14:20 Overview of on-going clinical trials with stem cells

Speaker: Prof. Goran Petrovski.

14:20 – 14:35 Stem Cell Based Trials for AMD

Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA

14:35 – 14:50 Clinical trial in opto-genetics.

Speaker: Prof. Isabelle Audo, INSERM, Paris, France.

14:50 – 15:00 How to discriminate between real treatments offers and quacks.

Speaker: Martin Smedstad Oslo, Norway.

15:00 – 15:30 Coffee break.

15:30 – 16:00 K.2.3

Keynote: Restoration of vision

Speaker: Prof. Mark S. Humayun University of Southern California, Los Angeles, USA.

16:00 – 17:00 P.2.4. Innovations in Ophthalmology.

Moderators: Christina Fasser and Prof. Einar Stefánsson.

16:00 – 17:00 L.2.4 Rehabilitation and mobility training.

Moderators: Vala Jóna Garðarsdóttir and Rósa María Hjörvar Iceland.

16:00 - 16:15 Mobility training and mobility tools.

Speaker: Vala Jóna Garðarsdóttir. National institute for the blind in Iceland.

16:15 – 16:30 Reading with auxiliary aids.

Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland.

16:30-16:45 The assistive technology, aps etc.

Speakers: Baldur Snær Sigurðsson and Hlynur Þór Agnarsson.

16:45 - 17:00 Coping with visual and hearing impairment.



Speakers: Halla Dís Hallfreðsdóttir and Elín Yr Hafdisardóttir Arnardóttir.

Saturday 11th June.

08:30–10:00 P.3.1 New Developments in IRD.

Moderator: Prof. Michael Larsen.

08:30-08:50 Accessing Genetic Testing for IRDs: The Patient Perspective.

Speaker: Fiona Waters, Retina International, Dublin, Ireland

08:50-09:10 ABCA4 retinal dystrophies

Speaker: Frans Cremers, Radboud University, Nijmegen, Netherlands

09:10- 09:30 Ragnheidur Bragadottir and Josephine Prener Holtan: Luxturna treatment in Norway

09:30-10:00 Masayo Takahashi: the first clinical trial with iPScells

08:30-10:00 L.3.1 Clinical trials and therapies from a patient's perspective.

Moderator: Martin Smedstad, Oslo, Norway. TBC.

08:30 – 08:50 Overview and future on on-going clinical trials.

Speaker Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada.

08:50 – 09:10 RPE65 - the first gene therapy on the market.

Speaker: Dr. Daniel Chung, Philadelphia, USA.

09:10 – 09:30 Oligonucleotides - a hope for all?

Speaker: Prof. Bart Leroy, Gent University, Ghent, Belgium.

09:30 – 09:50 My personal experience of gene therapy.

Speaker: Camilla Jensen, Oslo, Norway

10:00 – 10.30 Coffee break.

10:30 – 12:00 P.3.2 Stem cells and cell-based therapies of retinal diseases.

Moderator Dr. Goran Petrovski, Oslo, Norway.

10;30 – 10:45: Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside.

Speaker: Prof. Kapil Bharti (NIH/NEI), Bethesda, USA.



10:45 – 11:00 Towards stem cell-based therapy in retinal degeneration.
Speaker: Anders Kvanta Stockholm, Sweden.

11:00 – 11:30 Subretinal implantation of primary human RPE cells in minipig eyes.
Speaker: Dr. Goran Petrovski, Oslo, Norway.

11:30 – 12:00 Epigenetic characterization during differentiation from iPS to RPE cells in AMD. Speaker: Dr. Cristina Zibetti, Oslo, Norway.

10:30 - 12:00 L 3.2 Retina International - the global challenges.
Moderator: Kristinn Halldor Einarsson, Iceland.

12:00 - 13:00 Lunch.

13:00 – 14:00 K.3.1 Keynote: Gene based therapies of retinal diseases.
Speaker: Prof. Artur Cideciyan, University of Pennsylvania, Philadelphia, USA.

14:00 – 15:00 P.3.3 Gene based therapies of retinal diseases.
Moderator Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland.
Send her e-mail

14:00 – 14:15 CPK850 gene therapy in RLPB1 patients.
Speaker: Prof. Anders Kvanta, Karolinska Institute, Stockholm, Sweden

14:15 – 14:30 Retinal gene therapy trials - investigators point of view.
Speaker: Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland.

14:30 – 14:45 Retinal gene therapy in choroideremia patients - surgical aspects.
Speaker: Prof. Ilkka Immonen, Helsinki University Hospital, Helsinki, Finland.

14:45 – 15:00 Gene therapy of Usher syndrome.
Speaker: Prof. Isabelle Audo, Institute de la Vision, Paris, France.

14:00 - 15:00 L.3.4 Programme in icelandic for the public.

15:00 Closing ceremony.